Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 19 clinical trials
Flotetuzumab for Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Following Allogeneic Hematopoietic Cell Transplantation (Allo-HCT)

resulting in improved patient outcomes. Furthermore, administration of a donor lymphocyte infusion (DLI) (if available) in combination with flotetuzumab will be safe, tolerable and may provide additional

  • 0 views
  • 26 Apr, 2022
  • 1 location
Cytokine Induced Memory-like NK Cell Adoptive Therapy for Relapsed AML After Allogeneic Hematopoietic Cell Transplant

Donor Lymphocyte Infusion (DLI) following salvage chemotherapy is the one of the most widely used treatment approaches in patients who relapse after allogeneic hematopoietic cell transplant

  • 24 views
  • 06 Apr, 2022
  • 1 location
T-cell Receptor α/β Depleted Donor Lymphocyte Infusion

This pilot study is being conducted to treat patients who have a certain type of malignancy (lymphoid or myeloid) with immune effector cells after a T-cell depleted allogeneic hematopoietic cell transplantation (TCD HSCT). This study is designed to see whether an investigational cellular product of immune cells obtained from a …

cell transplantation
  • 0 views
  • 12 May, 2022
  • 1 location
Risk-adapted Donor Lymphocyte Infusion After Allo-HSCT in Children With Hematologic Malignancy

Allo-hsct is potentially curative method of treatment for children and adolescent with hematologic malignancy. However, relapses of disease after allo-hsct occur up to 50% of patients and constitute the main cause of mortality after HSCT. Donor lymphocytes infusion (DLI) is a form of immunotherapy based on developement of reaction "graft …

donor lymphocyte infusion
remission
chronic myeloid leukemia
myeloid leukemia
leukemia
  • 0 views
  • 22 Aug, 2021
  • 1 location
Ex-vivo Primed Memory Donor Lymphocyte Infusion to Boost Anti-viral Immunity After T-cell Depleted HSCT

To determine long-term outcomes, recurrence rates, and treatment needs in Polypoidal Choroidal Vasculopathy (PCV). Specifically, to describe the long-term outcomes, recurrence rates and treatment patterns PCV patients 5 years after first presentation. This study will also evaluate whether polyp closure within the first 12 months of therapy is associated with …

transplant conditioning
ejection fraction
  • 0 views
  • 10 Oct, 2021
  • 1 location
HMA+DLI vs DLI Preemptive Therapy Based on MRD for AL Undergoing Allo-HSCT

options for relapse include stopping immune suppression, re-induction of chemotherapy, donor lymphocyte infusion (DLI) or combination therapy. In this prospective randomized controlled study, the safety

  • 2 views
  • 14 Feb, 2022
  • 1 location
Study to Evaluate the Safety of a Gene and Cell Therapy Product in Participants With HIV That is Well-Controlled on Antiretroviral Therapy

This is a Phase 1 study to assess the safety of a gene and cell therapy for autologous donor lymphocyte infusion in HIV+ participants with well-controlled viremia on antiretroviral therapy.

atazanavir
antiretroviral therapy
viremia
HIV Vaccine
  • 0 views
  • 20 May, 2021
  • 2 locations
Extracorporeal Photopheresis Using Theraflex ECP for Patients With Refractory Chronic Graft Versus Host Disease (cGVHD)

Theraflex system in patients with refractory chronic graft versus host disease (cGVHD) after any type of hematopoietic stem cell transplantation or after donor lymphocyte infusion.

  • 1 views
  • 21 Jan, 2021
  • 7 locations
Blinatumomab Plus HLA-Mismatched Cellular Therapy for Relapsed/Refractory CD19+ ALL

blood mononuclear cells collected via pheresis from a haploidentical family member - the procedure is analogous to giving a donor lymphocyte infusion outside of the setting of an allogeneic stem cell

flow cytometry
cytopenias
cellular therapy
gilbert's syndrome
stem cell transplantation
  • 0 views
  • 13 Nov, 2021
  • 1 location
Haploidentical HCT for Severe Aplastic Anemia

This study is a prospective, single center phase II clinical trial in which patients with Severe Aplastic Anemia (SAA) ) will receive a haploidentical transplantation. The purpose of this study is to learn more about newer methods of transplanting blood forming cells donated by a family member that is not …

glomerular filtration rate
cyclophosphamide
fludarabine
ejection fraction
red blood cell transfusion
  • 5 views
  • 10 Sep, 2021
  • 1 location